POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC

被引：0

作者：

Thomas, M. ^{[1
]}

Grohe, C. ^{[2
]}

Eberhardt, W. ^{[3
]}

Rawluk, J. ^{[4
]}

Reck, M. ^{[5
]}

Laack, E. ^{[6
]}

Wesseler, C. ^{[7
]}

Rittmeyer, A. ^{[8
]}

Alt, J. ^{[9
]}

Reinmuth, N. ^{[10
]}

Griesinger, F. ^{[11
]}

Kern, J. ^{[12
]}

机构：

[1] Univ Klinikum Heidelberg, Thoraxonkol, Thoraxklin, Heidelberg, Germany

[2] Evangel Lungenklin, Berlin, Germany

[3] Univ Klin, Essen, Germany

[4] Univ Klinikum, Freiburg, Germany

[5] LungenClin Grosshansdorf GmbH, Grosshansdorf, Germany

[6] Haematoonkol Hamburg, Hamburg, Germany

[7] Asklepios Klin Hamburg Harburg, Hamburg, Germany

[8] Fachklin Lungenerkrankungen, Immenhausen, Germany

[9] Univ Med, Mainz, Germany

[10] Asklepios Fachkliniken, Munich, Germany

[11] Pius Hosp, Oldenburg, Germany

[12] Klinikum Wurzburg Mitte Standort Missioklin gGmbH, Wurzburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P908

引用

页码：295 / 295

页数：1

共 50 条

[21] Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Garon, Edward B.
Cho, Byoung Chul
Luft, Alexander
Alatorre-Alexander, Jorge
Geater, Sarayut Lucien
Kim, Sang-We
Ursol, Grygorii
Hussein, Maen
Lim, Farah Louise
Yang, Cheng-Ta
Araujo, Luiz Henrique
Saito, Haruhiro
Reinmuth, Niels
Medic, Nenad
Mann, Helen
Shi, Xiaojin
Peters, Solange
Mok, Tony
Johnson, Melissa
LUNG CANCER, 2023, 186
[22] Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
Reinmuth, N.
Cho, B. C.
Luft, A.
Alatorre Alexander, J. A.
Geater, S. Lucien
Laktionov, K.
Kim, S-W.
Ursol, G.
Hussein, M.
Lim, F. L.
Yang, C-T.
Araujo, L. H.
Saito, H.
Barrett, K.
Lowery, C.
Tattersfield, R.
Peters, S.
Garon, E. B.
Mok, T. S. K.
Johnson, M. L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S44 - S46
[23] First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
Liu, Wenjie
Huo, Gengwei
Chen, Peng
FRONTIERS IN PHARMACOLOGY, 2023, 14
[24] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
Chen, Pingyu
Wang, Xintian
Zhu, Shengwen
Li, Hongchao
Rui, Mingjun
Wang, Yingcheng
Sun, Haikui
Ma, Aixia
FRONTIERS IN PUBLIC HEALTH, 2022, 10
[25] Tremelimumab (T) plus durvalumab (D) plus chemotherapy (CT) in 1L metastatic NSCLC: Outcomes by blood tumor mutational burden (bTMB) in POSEIDON
Peters, Solange
Madison, Hisani
Oliner, Kelly
L'Hernault, Anne
Ratcliffe, Marianne
Barrett, Karen
Shi, Xiaojin
Garon, Edward B.
Mok, Tony
Johnson, Melissa L.
CANCER RESEARCH, 2023, 83 (08)
[26] Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
Lee, Dae Ho
Kim, Hye Ryun
Keam, Bhumsuk
Kato, Ken
Kuboki, Yasutoshi
Gao, Haiyan
Yovine, Alejandro
Robbins, Scott H. H.
Ahn, Myung-Ju
CANCER MEDICINE, 2023, 12 (15): : 16066 - 16075
[27] Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Rizvi, Naiyer A.
Cho, Byoung Chul
Reinmuth, Niels
Lee, Ki Hyeong
Luft, Alexander
Ahn, Myung-Ju
van den Heuvel, Michel M.
Cobo, Manuel
Vicente, David
Smolin, Alexey
Moiseyenko, Vladimir
Antonia, Scott J.
Le Moulec, Sylvestre
Robinet, Gilles
Natale, Ronald
Schneider, Jeffrey
Shepherd, Frances A.
Geater, Sarayut Lucien
Garon, Edward B.
Kim, Edward S.
Goldberg, Sarah B.
Nakagawa, Kazuhiko
Raja, Rajiv
Higgs, Brandon W.
Boothman, Anne-Marie
Zhao, Luping
Scheuring, Urban
Stockman, Paul K.
Chand, Vikram K.
Peters, Solange
JAMA ONCOLOGY, 2020, 6 (05) : 661 - 674
[28] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Marion Thibaudin
Jean-David Fumet
Benoist Chibaudel
Jaafar Bennouna
Christophe Borg
Jerome Martin-Babau
Romain Cohen
Marianne Fonck
Julien Taieb
Emeric Limagne
Julie Blanc
Elise Ballot
Léa Hampe
Marjorie Bon
Susy Daumoine
Morgane Peroz
Hugo Mananet
Valentin Derangère
Romain Boidot
Henri-Alexandre Michaud
Caroline Laheurte
Olivier Adotevi
Aurélie Bertaut
Caroline Truntzer
François Ghiringhelli
Nature Medicine, 2023, 29 : 2087 - 2098
[29] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial
Thibaudin, Marion
Fumet, Jean-David
Limagne, Emeric
Hampe, Lea
Daumoine, Susy
Derangere, Valentin
Laheurte, Caroline
Adotevi, Olivier
Truntzer, Caroline
Ghiringhelli, Francois
CANCER RESEARCH, 2024, 84 (07)
[30] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Thibaudin, Marion
Fumet, Jean-David
Chibaudel, Benoist
Bennouna, Jaafar
Borg, Christophe
Martin-Babau, Jerome
Cohen, Romain
Fonck, Marianne
Taieb, Julien
Limagne, Emeric
Blanc, Julie
Ballot, Elise
Hampe, Lea
Bon, Marjorie
Daumoine, Susy
Peroz, Morgane
Mananet, Hugo
Derangere, Valentin
Boidot, Romain
Michaud, Henri-Alexandre
Laheurte, Caroline
Adotevi, Olivier
Bertaut, Aurelie
Truntzer, Caroline
Ghiringhelli, Francois
NATURE MEDICINE, 2023, 29 (08) : 2087 - +

← 1 2 3 4 5 →